Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. Issue 31 (31st July 2020)

• Record Type: Journal Article
• Authors: Krasniqi, Eriseld; Barchiesi, Giacomo; Mazzotta, Marco; Pizzuti, Laura; Villa, Alice; Barba, Maddalena; Vici, Patrizia
• Other Names: Saranathan. Maya section editor.
• Is Part Of: Medicine. Volume 99:Issue 31(2020)
• Publication Date: 2020-07-31
• Subjects: everolimus -- exemestane -- metastatic breast cancer; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000021211
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). Patient concerns: We herein report on a patient affected by HR+ HER2– MBC treated with radical surgery after neoadjuvant chemotherapy, who relapsed early on adjuvant tamoxifen, progressed rapidly on first line anastrozole, and failed treatment with third line capecitabine. Diagnoses: Metastatic luminal breast cancer progressed under standard endocrine therapy and chemotherapy. Interventions: Third line with Eve plus Exe was given after chemotherapy. Outcomes: Patient experienced a 5-year progression free interval. Lessons: Eve plus Exe remains a valid option in HR+HER2– MBC.